Grufity logoGrufity logo
StocksFundsScreenerSectorsWatchlists
AZYO

AZYO - Aziyo Biologics, Inc. Stock Price, Fair Value and News

Market Closed
Watchlist

AZYO Stock Price

View Fullscreen

AZYO RSI Chart

AZYO Valuation

Market Cap

24.8M

Price/Earnings (Trailing)

-0.74

Price/Sales (Trailing)

0.69

EV/EBITDA

-1.48

Price/Free Cashflow

-1.35

AZYO Price/Sales (Trailing)

AZYO Profitability

EBT Margin

-93.98%

Return on Equity

-24.69%

Return on Assets

-61.89%

Free Cashflow Yield

-73.95%

AZYO Fundamentals

AZYO Revenue

Revenue (TTM)

36.1M

Rev. Growth (Yr)

4.75%

Rev. Growth (Qtr)

-40.49%

AZYO Earnings

Earnings (TTM)

-33.8M

Earnings Growth (Yr)

1.64%

Earnings Growth (Qtr)

8.23%

Breaking Down AZYO Revenue

Last 7 days

-4.6%

Last 30 days

-33.0%

Last 90 days

-36.2%

Trailing 12 Months

-80%

How does AZYO drawdown profile look like?

AZYO Financial Health

Current Ratio

0.87

Debt/Equity

0.18

Debt/Cashflow

-0.71

AZYO Investor Care

Shares Dilution (1Y)

24.96%

Diluted EPS (TTM)

-2.07

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
202338.1M35.8M36.1M0
202224.5M28.5M32.5M36.6M
202145.7M49.3M49.0M20.5M
202042.8M42.8M42.7M42.7M
201900042.9M

Tracking the Latest Insider Buys and Sells of Aziyo Biologics, Inc.

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Jun 21, 2023
mills c randal
sold (taxes)
-18,730
2.41
-7,772
president and ceo
Jun 21, 2023
mills c randal
acquired
-
-
22,474
president and ceo
Apr 27, 2023
mills c randal
acquired
-
-
44,947
president and ceo
Mar 27, 2023
birchview capital, lp
bought
15,870
1.587
10,000
-
Mar 24, 2023
birchview capital, lp
bought
27,078
1.3539
20,000
-
Mar 23, 2023
birchview capital, lp
bought
164,010
1.491
110,000
-
Mar 09, 2023
englese thomas
sold
-1,242
4.3
-289
chief commercial officer
Mar 08, 2023
englese thomas
acquired
-
-
937
chief commercial officer
Mar 08, 2023
ferguson matthew
acquired
-
-
1,287
chief financial officer
Dec 15, 2022
colpman david
bought
12,082
3.9
3,098
-

1–10 of 43

Which funds bought or sold AZYO recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Feb 26, 2024
Virtu Financial LLC
new
-
24,000
24,000
-%
Feb 15, 2024
Nantahala Capital Management, LLC
added
100
4,768,500
7,128,000
0.21%
Feb 14, 2024
BANK OF AMERICA CORP /DE/
new
-
11.00
11.00
-%
Feb 14, 2024
Prosight Management, LP
sold off
-100
-36,599
-
-%
Feb 14, 2024
MILLENNIUM MANAGEMENT LLC
new
-
45,775
45,775
-%
Feb 14, 2024
VANGUARD GROUP INC
added
16.5
275,272
637,597
-%
Feb 14, 2024
Royal Bank of Canada
added
1.85
-
-
-%
Feb 13, 2024
Qube Research & Technologies Ltd
unchanged
-
1.00
2.00
-%
Feb 13, 2024
NORTHERN TRUST CORP
new
-
28,780
28,780
-%

1–10 of 26

Are Funds Buying or Selling AZYO?

Are funds buying AZYO calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own AZYO
No. of Funds

Unveiling Aziyo Biologics, Inc.'s Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 20, 2024
birchview capital, lp
8.76%
1,655,184
SC 13G/A
Feb 14, 2024
nantahala capital management, llc
9.9%
1,912,776
SC 13G
Feb 07, 2024
hirschman orin
9.9%
1,886,556
SC 13G/A
Oct 06, 2023
highcape capital, l.p.
0.3%
48,931
SC 13D/A
Apr 07, 2023
birchview capital, lp
13.9%
1,655,184
SC 13G/A
Mar 21, 2023
endurant capital management lp
4.88%
576,253
SC 13G/A
Feb 14, 2023
endurant capital management lp
10.67%
1,259,544
SC 13G/A
Feb 14, 2023
endurant capital management lp
10.67%
1,259,544
SC 13G/A
Feb 13, 2023
birchview capital, lp
12.8%
1,515,184
SC 13G/A
Dec 15, 2022
birchview capital, lp
12.7%
1,502,123
SC 13G/A

Recent SEC filings of Aziyo Biologics, Inc.

View All Filings
Date Filed Form Type Document
Feb 20, 2024
3/A
Insider Trading
Feb 20, 2024
4/A
Insider Trading
Feb 20, 2024
SC 13G/A
Major Ownership Report
Feb 14, 2024
424B3
Prospectus Filed
Feb 14, 2024
SC 13G
Major Ownership Report
Feb 07, 2024
SC 13G/A
Major Ownership Report
Feb 02, 2024
4
Insider Trading
Feb 02, 2024
4
Insider Trading
Feb 02, 2024
4
Insider Trading
Feb 02, 2024
8-K
Current Report

Aziyo Biologics, Inc. News

Latest updates
Yahoo Finance6 months ago

Aziyo Biologics, Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
Income Statement (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q3
Revenue-40.5%6,127,00010,296,00013,050,0006,587,0005,849,00012,638,00011,495,00011,490,00011,485,00012,160,00012,884,00012,466,00011,774,0008,579,0009,863,00010,500,50011,138,000
Gross Profit189.9%2,841,000980,0006,331,0001,293,5002,939,0004,898,0004,281,000-6,352,0003,689,0005,614,0006,329,0006,021,0005,541,0003,784,0005,215,000-5,543,000
Operating Expenses1.5%10,212,00010,065,00012,749,00011,616,00011,906,00013,080,00011,203,0006,907,00010,665,00010,209,00010,028,0009,984,0008,232,0007,547,000---
  S&GA Expenses-22.6%2,802,0003,618,0005,356,0003,712,5004,379,0005,406,0004,818,0002,370,0004,783,0004,799,0004,703,0004,720,0004,301,0004,062,0004,482,000-4,435,000
  R&D Expenses-52.4%557,0001,171,0001,803,0001,487,5001,723,0002,617,0002,272,0001,864,0002,289,0001,881,0001,720,0001,973,0001,264,0001,408,0001,309,000-507,000
EBITDA Margin10.9%-0.67-0.75-0.68-0.72-1.06-1.11-1.00-1.04-0.24-0.21-0.28-0.29-0.06-0.06-0.06-0.06-
Interest Expenses-5.0%1,448,0001,524,0001,544,0001,452,0001,247,0001,204,0001,215,0001,290,0001,328,0001,351,0001,355,0001,385,0001,465,0001,410,0001,373,000-1,249,000
Income Taxes0%12,00012,00012,000-2,00012,00012,00012,00012,00012,00018,00013,0008,0008,0005,0005,000-8,000
Earnings Before Taxes19.8%-8,507,000-10,609,000-7,962,000-6,812,500-11,017,000-9,386,000-8,137,000-14,549,000-8,304,000-2,367,000-5,054,000-5,348,000-6,723,000-5,173,000-4,555,000--3,096,000
EBT Margin7.6%-0.94-1.02-0.92-0.97-1.32-1.42-1.36-1.48-0.43-0.40-0.49-0.51-0.28-0.28-0.28-0.28-
Net Income8.2%-9,747,000-10,621,000-7,974,000-5,440,000-9,910,000-9,398,000-8,149,000-9,064,000-8,316,000-2,385,000-5,067,000-5,356,000-6,731,000-5,178,000-4,560,000--3,104,000
Net Income Margin1.2%-0.94-0.95-0.86-0.90-1.12-1.22-1.14-1.21-0.43-0.40-0.49-0.51-0.28-0.28-0.28-0.28-
Free Cashflow-107.7%-5,162,000-2,485,000-5,382,000-5,345,000-1,944,000-10,955,000-7,384,000-6,412,000-3,195,000-903,000-5,305,000-5,483,000-1,665,000-4,018,000-3,100,000--
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q4
Assets4.3%55.0052.0061.0069.0061.0053.0060.0067.0060.0070.0074.0083.0046.0046.0045.0045.00
  Current Assets8.3%39.0036.0043.0051.0044.0035.0041.0047.0039.0048.0052.0060.0022.00--18.00
    Cash Equivalents56.2%15.009.0012.0017.008.0017.0022.0030.0023.0028.0030.0040.002.001.001.003.00
  Inventory-29.9%7.009.0011.004.0010.0010.0010.003.0010.0010.0010.0010.0010.00--7.00
  Net PPE-88.1%0.001.001.000.001.001.001.000.001.001.001.001.001.00--1.00
Liabilities12.9%84.0074.0073.0074.0072.0054.0053.0054.0052.0055.0058.0062.0064.0061.0058.0055.00
  Current Liabilities4.4%45.0043.0041.0043.0040.0035.0027.0026.0023.0024.0025.0027.0026.00--18.00
  Short Term Borrowings------8.008.008.008.008.009.006.003.00--2.00
  Long Term Debt1.4%25.0025.0025.0024.0020.007.009.0010.0012.0014.0016.0018.0021.00--20.00
    LT Debt, Non Current1.4%25.0025.0025.0024.0020.007.009.0010.0012.0014.0016.0018.0021.00--20.00
Shareholder's Equity1.8%1371341341331221217.0014.008.0015.0016.0021.000.002.002.002.00
  Retained Earnings-6.2%-166-156-145-138-132-122-113-105-96.03-87.71-85.33-80.26-74.90---56.94
  Additional Paid-In Capital1.8%137134134133122121120119104103102101---2.00
Shares Outstanding5.0%17.0016.0016.0014.0014.0014.0014.0010.0010.0010.0010.003.001.001.001.001.00
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q3
Cashflow From Operations-112.5%-5,100-2,400-5,200-5,211-1,827-10,700-7,350-6,387-3,098-787-5,174-5,368-1,229-3,991-3,038--
  Share Based Compensation-10.3%6166876847742981,4701,1059731,00088567759558.0072.0054.00--
Cashflow From Investing27.1%-62.00-85.00-182-134-117-255-34.00-25.00-97.00-116-131-115-436-27.00-62.00--
Cashflow From Financing54868.4%10,406-19.0014814,267-2,320-3,000-86914,214-2,547-1,230-3,72643,3712,2694,4321,136--

AZYO Income Statement

2023-06-30
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
$ in Thousands
3 Months Ended6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS    
Net sales$ 10,296$ 12,638$ 23,346$ 24,133
Cost of goods sold9,3167,74016,03514,954
Gross profit9804,8987,3119,179
Sales and marketing3,6185,4068,97410,224
General and administrative4,0054,7117,6848,736
Research and development1,1712,6172,9744,889
FiberCel litigation costs, net1,2713463,182434
Total operating expenses10,06513,08022,81424,283
Loss from operations(9,085)(8,182)(15,503)(15,104)
Interest expense1,5241,2043,0682,419
Loss before provision for income taxes(10,609)(9,386)(18,571)(17,523)
Income tax expense12122424
Net loss$ (10,621)$ (9,398)$ (18,595)$ (17,547)
Net loss per share - basic (in dollar per share)$ (0.65)$ (0.69)$ (1.15)$ (1.29)
Net loss per share - diluted (in dollar per share)$ (0.65)$ (0.69)$ (1.15)$ (1.29)
Weighted average common shares outstanding - basic16,223,91913,620,19616,208,90513,597,243
Weighted average common shares outstanding - diluted16,223,91913,620,19616,208,90513,597,243

AZYO Balance Sheet

2023-06-30
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Jun. 30, 2023
Dec. 31, 2022
Current assets:  
Cash$ 9,296$ 16,989
Accounts receivable, net of credit loss reserve of $921 and $87, respectively6,3176,830
Inventory9,27410,052
Receivables of FiberCel litigation costs8,87613,813
Prepaid expenses and other current assets2,3633,015
Total current assets36,12650,699
Property and equipment, net1,4671,403
Intangible assets, net13,37015,069
Operating lease right-of-use assets and other1,3661,670
Total assets52,32968,841
Current liabilities:  
Accounts payable3,2272,328
Accrued expenses and other current liabilities11,72410,103
Payables to tissue suppliers2,4603,152
Current portion of revenue interest obligation10,3668,990
Contingent liability for FiberCel litigation14,47017,360
Current operating lease liabilities and other620682
Total current liabilities42,86742,615
Long-term debt24,92724,260
Long-term revenue interest obligation5,6015,916
Long-term operating lease liabilities711956
Other long-term liabilities351127
Total liabilities74,45773,874
Commitments and contingencies (Note 8)
Stockholders' equity (deficit):  
Additional paid-in capital134,439132,939
Accumulated deficit(156,583)(137,988)
Total stockholders' deficit(22,128)(5,033)
Total liabilities and stockholders' deficit52,32968,841
Class A Common stock  
Stockholders' equity (deficit):  
Common stock1212
Class B Common stock  
Stockholders' equity (deficit):  
Common stock$ 4$ 4

About Aziyo Biologics, Inc.

AZYO

Aziyo Biologics, Inc. Frequently Asked Questions


What is the ticker symbol for Aziyo Biologics, Inc.? What does AZYO stand for in stocks?

AZYO is the stock ticker symbol of Aziyo Biologics, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Aziyo Biologics, Inc. (AZYO)?

As of Sat Sep 30 2023, market cap of Aziyo Biologics, Inc. is 24.85 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of AZYO stock?

You can check AZYO's fair value in chart for subscribers.

What is the fair value of AZYO stock?

You can check AZYO's fair value in chart for subscribers. The fair value of Aziyo Biologics, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Aziyo Biologics, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for AZYO so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Aziyo Biologics, Inc. a good stock to buy?

The fair value guage provides a quick view whether AZYO is over valued or under valued. Whether Aziyo Biologics, Inc. is cheap or expensive depends on the assumptions which impact Aziyo Biologics, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for AZYO.

What is Aziyo Biologics, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Sat Sep 30 2023, AZYO's PE ratio (Price to Earnings) is -0.74 and Price to Sales (PS) ratio is 0.69. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. AZYO PE ratio will change depending on the future growth rate expectations of investors.